8-K: CONMED Reports Q2 2026 Results, Updates Guidance

CONMED Corporation announced second quarter 2026 financial results, showing modest sales growth and a significant increase in adjusted diluted EPS, while updating full-year guidance.

Summary

• CONMED Corporation reported second quarter 2026 sales of $343.5 million, a 0.3% increase year-over-year as reported, and a 0.5% decrease on a constant currency basis.
• Excluding strategic exits from GI product offerings, net sales grew 6.0% on an organic constant currency basis.
• Domestic sales decreased 8.0% but increased 2.5% on an organic basis, while international sales saw a 10.8% increase as reported.
• GAAP diluted earnings per share (EPS) were $0.77, up 11.6%, and adjusted diluted EPS were $1.38, up 20.0%.
• Both GAAP and adjusted EPS benefited from a $0.21 per share refund related to IEEPA tariffs.
• The company updated its full-year 2026 guidance, now expecting net sales between $1,358 million and $1,373 million, with organic constant currency net sales growth projected at 5.0% to 6.0%.
• Full-year adjusted diluted EPS is now forecasted to be between $4.48 and $4.60.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong organic growth and EPS performance exceeding expectations, coupled with an updated positive full-year guidance. The strategic exits are a necessary part of portfolio optimization, and the underlying business performance is robust.

Positives

• Organic constant currency net sales growth of 6.0% in Q2 2026, excluding strategic exits.
• Adjusted diluted EPS increased by 20.0% year-over-year to $1.38 in Q2 2026.
• International sales showed strong growth, increasing 10.8% as reported and 9.9% on an organic constant currency basis.
• Positive impact from IEEPA tariff refunds ($0.21 per share) on both GAAP and adjusted EPS.
• Updated full-year 2026 guidance for net sales and adjusted diluted EPS reflects improved outlook.
• Net sales growth across both Orthopedic Surgery and General Surgery product lines on an organic constant currency basis.
• Strategic priorities advanced, including portfolio optimization and debt refinancing.

Negatives

• Reported net sales increased only 0.3% year-over-year, and decreased 0.5% on a constant currency basis.
• Domestic sales decreased 8.0% as reported, although organic growth was positive at 2.5%.
• The strategic exits of GI product offerings negatively impacted reported sales figures.

Risks

• Potential risks and uncertainties that could cause actual results to differ materially from forward-looking statements, as detailed in the Company's Annual Report on Form 10-K and other SEC filings.
• Factors such as general industry and economic conditions could impact future performance.
• Compliance with European Union's Medical Device Regulations (MDR) incurred costs.

Future Outlook

The company updated its full-year 2026 financial guidance to reflect Q2 performance and an improved outlook for the second half of the year. Full-year net sales are now projected between $1,358 million and $1,373 million, with organic constant currency net sales growth expected between 5.0% and 6.0%. Adjusted diluted EPS is forecasted to be in the range of $4.48 to $4.60.

Management Comments

• "We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations."
• "Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace."
• "In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team."
• "We are updating our financial guidance for the full year 2026 today to reflect both our second quarter performance and our updated outlook for the balance of the year."
• "Looking ahead, our team remains focused on disciplined execution as we continue to position CONMED for quality, long-term growth and value creation."

Industry Context

StockSavvy.ai notes that CONMED's performance in Q2 2026, particularly its organic growth excluding strategic exits, aligns with a broader trend in the medical technology sector where companies are focusing on core competencies and optimizing product portfolios. The positive international sales growth also reflects global demand for advanced surgical solutions.

Comparison to Industry Standards

• CONMED's organic constant currency net sales growth of 6.0% in Q2 2026, excluding strategic exits, is a solid performance within the competitive medical device industry, where growth rates can vary significantly by sub-sector.
• The 20.0% increase in adjusted diluted EPS is a strong indicator of operational efficiency and margin improvement, a key focus for many companies in the sector aiming to offset inflationary pressures and supply chain challenges.
• The company's focus on key growth platforms like AirSeal and its expansion with Intuitive Surgical's da Vinci 5 platform positions it to compete effectively against larger players such as Medtronic, Johnson & Johnson (Medical Devices), and Stryker, who also invest heavily in robotic-assisted surgery and specialized surgical tools.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact expected from improved EPS and updated guidance, potentially leading to increased stock value.
• Employees: Continued focus on execution and growth may lead to job security and potential for performance-based incentives.
• Customers: Continued innovation and availability of key product lines like AirSeal are beneficial.
• Suppliers: Stable demand from core product lines supports ongoing supplier relationships.

Next Steps

• Continue execution of strategic priorities, including portfolio optimization and growth platform advancement.
• Focus on disciplined execution for long-term growth and value creation.
• Management to host a conference call on July 29, 2026, at 4:30 p.m. ET to discuss results.

Key Dates

Recommendation

The company delivered expected results with positive organic growth and EPS exceeding expectations, and has updated its guidance positively. However, the modest overall reported sales growth and the ongoing impact of strategic exits warrant a 'hold' rating until sustained, broader growth is demonstrated across all segments.

Keywords

CONMED Corporation, Medical Technology, Surgical Devices, Orthopedic Surgery, General Surgery, Financial Results, Earnings Per Share, Guidance Update